Zealand Pharma valuation
kr 229.60Change from previous close: −4.25%Absolute change: −kr 10.20
Valuation
The P/E ratio is 5.49. The average price target of 12 analysts is kr 386.08.
Data as of November 16, 2026
Zealand Pharma compared with similar companies
Zealand Pharma's P/E (trailing 12 months): 5.49, −67% against the median of a group of 9 similar companies (16.6).
| Metric | Zealand Pharma | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 5.49 | 16.6 | 5.49 – 38.0 | Middle |
| Forward P/E | 33.4 | 33.7 | 18.4 – 53.7 | Middle |
| EV/EBITDA | 1.15 | 14.5 | 9.80 – 24.9 | Low |
| Price/book | 0.94 | 3.89 | 1.74 – 8.03 | Low |
| Price/sales | 3.49 | 3.64 | 2.74 – 11.5 | Middle |
| Gross margin | 100.0% | 87.2% | 59.2% – 93.2% | High |
| Operating margin | 59.0% | 21.3% | 9.8% – 47.5% | High |
| Net margin | 67.2% | 21.2% | 8.4% – 45.7% | High |
| ROE | 19.1% | 19.1% | 7.7% – 27.7% | Middle |
| Debt/equity | 0.03 | 0.03 | 0.02 – 0.34 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- kr 16.05B
- Enterprise value
- kr 3.15B
- EV/revenue
- 0.69
Profitability and growth
- ROA
- 9.4%
- ROIC
- 8.4%
- Revenue growth (year over year)
- -92.0%
- Earnings growth (year over year)
- -47.6%
Financial health
- Total cash
- kr 13.51B
- Total debt
- kr 484M
- Current ratio
- 10.5
- Quick ratio
- 10.4
- Altman Z-Score
- 8.84
- Piotroski F-Score
- 3.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- kr 386.08
- Median price target
- kr 375.00
- High price target
- kr 550.00
- Low price target
- kr 280.00
- Analysts with a price target
- 12
- Consensus
- Buy
- Forward EPS
- kr 7.24
- EPS estimate, current year
- kr 33.04
Shares and trading
- Beta
- 0.47
- Average volume
- 393.6K
- Shares outstanding
- 66.33M
- Float
- 57.03M
- Institutional ownership
- 38.5%
- Insider ownership
- 0.5%
